Holen Sie sich die Stockscreener-App
95.41
0.72%
-0.69
Incyte Corp Aktie (INCY) Neueste Nachrichten
Incyte Corporation (INCY) Announces Retirement of Board Member H - GuruFocus
Incyte director Hervé Hoppenot retires from board effective immediately - Investing.com
Hervé Hoppenot resigns from Incyte’s board of directors - Investing.com
Incyte Announces Change to its Board of Directors - Business Wire
WINTON GROUP Ltd Makes New Investment in Incyte Corporation $INCY - MarketBeat
Ieq Capital LLC Has $27.52 Million Position in Incyte Corporation $INCY - MarketBeat
Incyte’s Blood Cancer Drug Shows Promise, But Hurdles Remain - Finimize
Incyte Corporation $INCY Shares Acquired by Investment Management Corp of Ontario - MarketBeat
Incyte stock rating reiterated by RBC, firm notes ’989 program viability - Investing.com
Jump Financial LLC Purchases 70,768 Shares of Incyte Corporation $INCY - MarketBeat
Amundi Purchases 101,220 Shares of Incyte Corporation $INCY - MarketBeat
Incyte releases data that shows promise in treating rare blood disease - Delaware Business Now
Sun Pharma Claims New Pill Distinct From Incyte's Hit Drug - Law360
Incyte (NASDAQ:INCY) Upgraded at Mizuho - MarketBeat
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia - BioSpace
Incyte stock holds Market Perform rating at Citizens on CALR therapy lead - Investing.com
Is Incyte Still Attractive After Its Strong 2025 Rally and DCF Valuation Gap? - Yahoo Finance
Is Incyte (INCY) Quietly Reframing Its R&D Story With Breakthrough Status And Legal Firepower? - Yahoo Finance
Incyte (INCY) Reports Promising Phase 1 Results for INCA033989 i - GuruFocus
Incyte’s experimental drug shows strong response in blood disorder By Investing.com - Investing.com Canada
Incyte’s experimental drug shows strong response in blood disorder - Investing.com
Incyte presents data showing 90% response rate for blood cancer drug - StreetInsider
Institution Moves: Why Incyte Corporation ICY stock stays undervaluedWatch List & Short-Term Trading Alerts - BỘ NỘI VỤ
Incyte (NASDAQ:INCY) Trading Down 6.6%Should You Sell? - MarketBeat
Incyte (INCY) Maintained as Equal-Weight by Morgan Stanley with Raised Price Target | INCY Stock News - GuruFocus
INCY: Wells Fargo Raises Price Target to $116 | INCY Stock News - GuruFocus
Incyte gains FDA Breakthrough designation for its candidate against essential thrombocythemia - marketscreener.com
Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status - Yahoo Finance
Incyte (INCY) Stock Receives Upgraded Rating and Price Target from Mizuho | INCY Stock News - GuruFocus
What's Going On With Incyte Stock Monday?Incyte (NASDAQ:INCY) - Benzinga
Incyte's New Therapy Shows Signs Of 'Disease-Modifying' Potential In Rare Blood Cancer - Sahm
Leerink Partners Adjusts Incyte Price Target to $128 From $103, Maintains Outperform Rating - marketscreener.com
Incyte stock price target raised to $128 by Leerink on mCALR data - Investing.com
Incyte Corporation $INCY Shares Purchased by American Century Companies Inc. - MarketBeat
Incyte Says Rare Blood Cancer Therapy Receives FDA Breakthrough Designation - marketscreener.com
Incyte Names Veteran Biopharma Attorney as New General Counsel - MyChesCo
Wells Fargo Adjusts Price Target on Incyte to $116 From $97, Maintains Overweight Rating - marketscreener.com
Mizuho upgrades Incyte stock rating to Outperform on promising ASH data - Investing.com
Incyte stock price target raised by BofA to $118 on promising blood disorder data - Investing.com
Mizuho Upgrades Incyte to Outperform From Neutral, Adjusts Price Target to $121 From $90 - marketscreener.com
First Trust Advisors LP Sells 12,101 Shares of Incyte Corporation $INCY - MarketBeat
Transcript : Incyte CorporationSpecial Call - marketscreener.com
Incyte (INCY) Secures FDA Breakthrough Therapy Designation for I - GuruFocus
Incyte (INCY) Reveals Promising Phase 1 Results for INCA033989 i - GuruFocus
Incyte (INCY) Receives FDA Breakthrough Therapy Designation for INCA033989 - GuruFocus
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025 - Business Wire
18,946 Shares in Incyte Corporation $INCY Bought by 1832 Asset Management L.P. - MarketBeat
Incyte: Buy At This Inflection Point (NASDAQ:INCY) - Seeking Alpha
Lido Advisors LLC Buys Shares of 13,529 Incyte Corporation $INCY - MarketBeat
Marshall Wace LLP Takes Position in Incyte Corporation $INCY - MarketBeat
Incyte Corporation $INCY Shares Bought by Fisher Asset Management LLC - MarketBeat
Dodge & Cox Sells 269,147 Shares of Incyte Corporation $INCY - MarketBeat
Insider Selling: Incyte (NASDAQ:INCY) EVP Sells 20,105 Shares of Stock - MarketBeat
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)December 3, 2025 - BioSpace
Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
VP Stein Sells 22,664 ($2.3M) Of Incyte Corp [INCY] - TradingView
Global Vitiligo Foundation Applauds Partnership Between Incyte and Winnie Harlow to Elevate Awareness and Understanding of Vitiligo - Yahoo Finance
Myeloproliferative Disorder Treatment Market Size Report 2032 - openPR.com
Mackenzie Financial Corp Has $24.67 Million Stock Position in Incyte Corporation $INCY - MarketBeat
Korea Investment CORP Decreases Stake in Incyte Corporation $INCY - MarketBeat
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding - Business Wire
Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel - BioSpace
Hsbc Holdings PLC Cuts Position in Incyte Corporation $INCY - MarketBeat
Incyte (INCY): Evaluating Valuation Following Recent Share Price Momentum - Yahoo Finance
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
Incyte Sets December Investor Lineup as Pipeline Progress Draws Market Attention - MSN
Incyte appoints Richard Hoffman as executive VP and general counsel By Investing.com - Investing.com Nigeria
Incyte appoints Richard Hoffman as executive VP and general counsel - Investing.com
3.07%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):